​

Nektar Therapeutics (NKTR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NKTR Stock Forecast

Nektar Therapeutics (NKTR) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $121.33, with a high of $192.00 and a low of $50.00. This represents a 223.98% increase from the last price of $37.45.

- $40 $80 $120 $160 $200 High: $192 Avg: $121.33 Low: $50 Last Closed Price: $37.45

NKTR Stock Rating

Nektar Therapeutics stock's rating consensus is Buy, based on 33 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (66.67%), 6 Hold (18.18%), 5 Sell (15.15%), and 0 Strong Sell (0.00%).

Buy
Total 33 0 5 6 22 Strong Sell Sell Hold Buy Strong Buy

NKTR Price Target Upside V Benchmarks

TypeNameUpside
StockNektar Therapeutics223.98%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3416
Avg Price Target$111.00$95.75$126.25
Last Closing Price$37.45$37.45$37.45
Upside/Downside196.40%155.67%237.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26192--12
Sep, 26192--12
Aug, 26191--11
Jul, 26181--10
Jun, 26181--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Will SoghikianLeerink Partners$130.00$41.17215.76%247.13%
Oct 12, 2026Alice NettletonUBS$53.00$41.1728.73%41.52%
Oct 01, 2026Roger SongJefferies$150.00$46.99219.22%300.53%
Sep 23, 2026Wedbush$50.00$60.97-17.99%33.51%
Jul 22, 2026Edward NashCanaccord Genuity$153.00$68.67122.80%308.54%
May 11, 2026Martin FanWedbush$80.00$81.89-2.31%113.62%
May 08, 2026Yasmeen RahimiPiper Sandler$192.00$83.37130.30%412.68%
Apr 21, 2026Wedbush$95.00$101.64-6.53%153.67%
Apr 20, 2026H.C. Wainwright$185.00$106.7573.30%393.99%
Mar 13, 2026Jay OlsonOppenheimer$140.00$73.2791.07%273.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 12, 2026UBSOverweightNeutralinitialise
Oct 08, 2026Raymond JamesMarket Performinitialise
Oct 05, 2026CitigroupBuyBuyhold
Oct 02, 2026H.C. WainwrightBuyBuyhold
Oct 01, 2026JefferiesBuyBuyhold
Oct 01, 2026William BlairOutperformOutperformhold
Sep 27, 2026BTIGBuyBuyhold
May 08, 2026Piper SandlerOverweightOverweighthold
Apr 22, 2026JefferiesBuyBuyhold
Apr 21, 2026WedbushNeutralNeutralhold

Financial Forecast

EPS Forecast

$-45 $-36 $-27 $-18 $-9 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.90$-29.51$-21.79$-8.68$-9.73---
Avg Forecast$-2.90$-2.13$-1.44$-0.72$-0.77$-0.70$-0.75$-0.76
High Forecast$-1.15$-0.99$-1.41$-0.46$-0.61$-0.38$-0.29$-0.21
Low Forecast$-3.89$-3.72$-1.47$-0.83$-0.93$-0.89$-1.05$-1.41
Surprise %1379.31%1285.45%1413.19%1105.56%1163.64%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$101.91M$92.06M$90.12M$98.43M$55.23M---
Avg Forecast$111.04M$91.46M$84.89M$104.74M$81.59M$80.39M$89.61M$139.94M
High Forecast$140.30M$144.24M$91.13M$155.05M$139.21M$81.71M$89.81M$233.57M
Low Forecast$59.55M$53.80M$72.68M$90.37M$37.45M$79.08M$89.41M$62.83M
Surprise %-8.23%0.65%6.17%-6.03%-32.30%---

Net Income Forecast

$-750M $-600M $-450M $-300M $-150M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-523.84M$-368.20M$-276.06M$-118.96M$-164.08M---
Avg Forecast$-555.71M$-614.62M$-276.06M$-121.91M$-172.26M$-121.25M$-127.20M$-143.64M
High Forecast$-444.57M$-491.70M$-220.84M$-86.95M$-116.82M$-72.93M$-54.65M$-40.74M
Low Forecast$-666.85M$-737.55M$-331.27M$-156.88M$-176.13M$-169.57M$-199.75M$-268.58M
Surprise %-5.74%-40.09%--2.42%-4.75%---

NKTR Forecast FAQ

Is Nektar Therapeutics stock a buy?

Nektar Therapeutics stock has a consensus rating of Buy, based on 33 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 6 Hold, 5 Sell, and 0 Strong Sell, reflecting a consensus that Nektar Therapeutics is a favorable investment for most analysts.

What is Nektar Therapeutics's price target?

Nektar Therapeutics's price target, set by 33 Wall Street analysts, averages $121.33 over the next 12 months. The price target range spans from $50 at the low end to $192 at the high end, suggesting a potential 223.98% change from the previous closing price of $37.45.

How does Nektar Therapeutics stock forecast compare to its benchmarks?

Nektar Therapeutics's stock forecast shows a 223.98% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nektar Therapeutics over the past three months?

  • October 2026: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Nektar Therapeutics’s EPS forecast?

Nektar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.7, marking a -92.81% decrease from the reported $-9.73 in 2025. Estimates for the following years are $-0.75 in 2027, and $-0.76 in 2028.

What is Nektar Therapeutics’s revenue forecast?

Nektar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $80.39M, reflecting a 45.56% increase from the reported $55.23M in 2025. The forecast for 2027 is $89.61M, and $139.94M for 2028.

What is Nektar Therapeutics’s net income forecast?

Nektar Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-121M, representing a -26.10% decrease from the reported $-164M in 2025. Projections indicate $-127M in 2027, and $-144M in 2028.